Evidence map›Paper›PMID 40386239›Full record

SynthesisPeerJ2025

Comparative efficacy of targeted therapy, chemotherapy and their combination for advanced cholangiocarcinoma: a systematic review and network meta-analysis.

Zhoujun Liao, Zhuoyue Yao, Zhiqing Yang, Shaohua Yang, Wenjuan Gu, Huijie Wang, Lingyan Deng

Abstract readSystematic ReviewComparative StudyNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhoujun Liao *Department of General Surgery, Panzhihua College Affiliated Hospital, Panzhihua University, Panzhihua, Panzhihua, China.
Zhuoyue Yao *Beijing TianTan Hospital, Beijing, China.
Zhiqing YangJiangxi Dexing Hospital, Shangrao, China.
Shaohua YangThe First People's Hospital of Qujing City, Qujing, China.
Wenjuan GuTianjin Kanghui Hospital, Tianjin, China.
Huijie WangJincheng People's Hospital of Shanxi Province, Jincheng, China.
Lingyan DengMaternal and Child Healthcare Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cholangiocarcinoma is a malignant tumor with a poor prognosis. Multiple randomized controlled trial (RCT) have shown conflicting benefits of different therapies. The study was to assess the effectiveness of chemotherapy (CT), targeted therapy (TT) and both of them (targeted therapy + chemotherapy; TT+CT) for advanced cholangiocarcinoma by a systematic review and network meta-analysis. Methods: PubMed, EmBase, Medline, Cochrane were searched. Two reviewers independently selected published reports of RCT comparing any targeted therapy, chemotherapy and targeted therapy combined with chemotherapy Results: We included 13 RCT involving 1,914 patients. We revealed a differential reporting of outcomes. All three treatments significantly reduced the HR in OS and PFS when compared with the placebo. HR and MD values of OS and PFS in TT+CT group were significantly better than those in the other two groups. Only targeted therapy can significantly improve PFS in patients. Conclusions: 1) All treatments significantly reduced the hazard ratio in OS and PFS when compared with the placebo; 2) HR and MD values of OS and PFS in TT+CT group were significantly better; 3) Only targeted therapy alone significantly increased the PFS of patients, thereby improving the quality of life of patients.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsCholangiocarcinomaMolecular Targeted TherapyHumansProgression-Free SurvivalRandomized Controlled Trials as TopicTreatment OutcomeAntineoplastic AgentsAdvanced cholangiocarcinomaChemotherapyComparative effectiveness reviewSystematic reviewTargeted therapy

Identifiers

PMID40386239
PMCPMC12085113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.